Treatment options for managing obesity in chronic kidney disease

Parvathareddy, Vishnu P; Ella, Krishiv M; Shah, Maulin; Navaneethan, Sankar D.

doi:10.1097/mnh.0000000000000727

Cited by 3 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About one-third of US adults are obese (BMI > 30 kg/ m 2 ) and obesity is an independent risk factor for CKD [4].…”

Section: Discussionmentioning

confidence: 99%

Acute post-transplant oxalate nephropathy: A case report and review of the literature

Daniel,

Francois,

Azemi

2024

Arch Organ Transplant

View full text Add to dashboard Cite

Calcium oxalate deposition in the kidney allograft remains an underappreciated cause of acute graft dysfunction. Diagnoses such as acute rejection, infection, hydronephrosis, and fluid collections are more immediately considered in the early post-transplant period. Risk factors include hyperoxaluria due to chronic fat malabsorption (post gastric bypass, inflammatory bowel disease), a diet rich in salt or animal protein, vitamin C ingestion, volume depletion, diabetes, and delayed graft function. We present the case of a patient who developed acute kidney injury secondary to oxalate nephropathy at 3 months post-transplant. Renal function improved with medical management, including volume repletion, calcium carbonate, and potassium citrate, without the need for hemodialysis. As more dialysis patients with morbid obesity requiring bariatric surgery, diabetes, and metabolic syndrome are being considered for renal transplantation, this entity merits more careful attention both prior to and after transplantation.

show abstract

“…About one-third of US adults are obese (BMI > 30 kg/ m 2 ) and obesity is an independent risk factor for CKD [4].…”

Section: Discussionmentioning

confidence: 99%

Acute post-transplant oxalate nephropathy: A case report and review of the literature

Daniel,

Francois,

Azemi

2024

Arch Organ Transplant

View full text Add to dashboard Cite

show abstract

“…The LEADER RCT ( 33 ) confirmed that Liraglutide can slow the occurrence and progression of DKD and alleviate the recurrence of type 2 diabetes after metabolic surgery. Therefore, the use of Liraglutide after metabolic surgery may provide additional renal protective benefits ( 34 ). Some medications may potentiate weight loss but are not FDA approved for obesity.…”

Section: Impact Of Weight Loss On Renal Function In Diabetic Patientsmentioning

confidence: 99%

The impact of weight loss on renal function in individuals with obesity and type 2 diabetes: a comprehensive review

Gong,

Zeng,

2024

Front. Endocrinol.

View full text Add to dashboard Cite

Obesity and Type 2 Diabetes (T2D) are two highly prevalent diseases that exhibit a complex interplay between them. Obesity serves as a primary risk factor for the development of T2D, and conversely, individuals with T2D often exhibit comorbid obesity. Renal dysfunction emerges as a critical consequence of the convergence of obesity and Type 2 Diabetes, contributing significantly to the overall burden of complications associated with these conditions. Recognizing the profound implications of renal dysfunction in individuals contending with both obesity and Type 2 Diabetes, interventions targeting weight loss have gained prominence as potential therapeutic avenues. Weight loss not only addresses the primary risk factor of obesity but also holds the promise of mitigating the progression of Type 2 Diabetes and its associated renal complications. This comprehensive review aims to explore the impact of weight loss on renal function in individuals contending with the convergence of obesity and T2D.

show abstract

CKD therapy to improve outcomes of immune-mediated glomerular diseases

Anders

Fernández-Juárez

Vaglio

et al. 2023

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

The management of IgA nephropathy, membranous nephropathy, lupus nephritis, ANCA-associated vasculitis, C3 glomerulonephritis, autoimmune podocytopathies and other immune-mediated glomerular disorders is focused on two major treatment goals, namely preventing overall mortality and the loss of kidney function. As minimizing irreversible kidney damage best serves both goals, the management of immune-mediated kidney disorders must focus on the two central pathomechanisms of kidney function decline, i.e. controlling the underlying immune disease process, e.g. with immunotherapies, and controlling the non-immune mechanisms of chronic kidney disease (CKD) progression. Here we review the pathophysiology of these non-immune mechanisms of CKD progression and discuss non-drug and drug interventions to attenuate CKD progression in immune-mediated kidney disorders. Non-pharmacological interventions include reducing salt intake, normalizing body weight, avoiding superimposed kidney injuries, smoking cessation, and regular physical activity. Approved drug interventions include inhibitors of the renin-angiotensin-aldosterone system and of the sodium-glucose-transporter-2. Numerous additional drugs to improve CKD care are currently being tested in clinical trials. Here we discuss about how and when to use these drugs in the different clinical scenarios of immune-mediated kidney diseases.

show abstract

Treatment options for managing obesity in chronic kidney disease

Cited by 3 publications

References 43 publications

Acute post-transplant oxalate nephropathy: A case report and review of the literature

Acute post-transplant oxalate nephropathy: A case report and review of the literature

The impact of weight loss on renal function in individuals with obesity and type 2 diabetes: a comprehensive review

CKD therapy to improve outcomes of immune-mediated glomerular diseases

Contact Info

Product

Resources

About